RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DEODATO M
Collezione AO Cuneo

Items : 3

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. in British journal of haematology / Br J Haematol. 2025 Mar;206(3):924-929. doi: 10.1111/bjh.19976. Epub 2025 Jan 7.

2025
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Vitale C; Coscia M; Bruno B; Rambaldi A; Laurenti L; Krampera M; Gaidano G; Rivela P; Quaglia FM; Quaresmini G; Moia R; Innocenti I; Deodato M; Frustaci AM; Catania G; Montalbano MC; Perutelli F; Boccellato E;

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

2022
AO Cuneo
AOU Città della Salute di Torino

Tedeschi A; Montillo M; Zamprogna G; Marinoni S; Ferrario A; Tani M; Varettoni M; Borella C; Ferrarini I; Sanna A; Motta M; Ibatici A; Orsucci L; Massaia M; Vitale C; Vanazzi A; Mauro FR; Quaresmini G; Visentin A; Reda G; Murru R; Laurenti L; Sportoletti P; Frustaci AM; Deodato M;